MX340055B - Metodos y composiciones de nanoparticulas sin priones. - Google Patents
Metodos y composiciones de nanoparticulas sin priones.Info
- Publication number
- MX340055B MX340055B MX2011010825A MX2011010825A MX340055B MX 340055 B MX340055 B MX 340055B MX 2011010825 A MX2011010825 A MX 2011010825A MX 2011010825 A MX2011010825 A MX 2011010825A MX 340055 B MX340055 B MX 340055B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- prion
- nanoparticle compositions
- compositions
- free nanoparticle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S210/00—Liquid purification or separation
- Y10S210/902—Materials removed
- Y10S210/903—Nitrogenous
- Y10S210/905—Protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
La presente invención se refiere a composiciones sin priones que comprenden nanopartículas que comprenden fármacos insolubles en albúmina y sustancialmente en agua. También se proporcionan métodos para producir composiciones libres de o sin priones y métodos de extracción de proteínas de prión de las composiciones de nanopartículas. También se proporcionan métodos de uso de las composiciones, así como equipos útiles para la realización de los métodos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16966509P | 2009-04-15 | 2009-04-15 | |
US23805209P | 2009-08-28 | 2009-08-28 | |
PCT/US2010/031197 WO2010121000A1 (en) | 2009-04-15 | 2010-04-15 | Prion-free nanoparticle compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011010825A MX2011010825A (es) | 2012-01-20 |
MX340055B true MX340055B (es) | 2016-06-22 |
Family
ID=42982852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011010825A MX340055B (es) | 2009-04-15 | 2010-04-15 | Metodos y composiciones de nanoparticulas sin priones. |
Country Status (25)
Country | Link |
---|---|
US (3) | US20100297243A1 (es) |
EP (2) | EP3626233A1 (es) |
JP (3) | JP5781500B2 (es) |
KR (1) | KR20120044279A (es) |
CN (1) | CN102460167B (es) |
AU (1) | AU2010236382B2 (es) |
BR (1) | BRPI1012525A2 (es) |
CA (1) | CA2758913A1 (es) |
CY (1) | CY1122617T1 (es) |
DK (1) | DK2419732T3 (es) |
ES (1) | ES2764100T3 (es) |
HR (1) | HRP20192259T1 (es) |
HU (1) | HUE047376T2 (es) |
IL (1) | IL215765A (es) |
LT (1) | LT2419732T (es) |
ME (1) | ME03596B (es) |
MX (1) | MX340055B (es) |
MY (1) | MY175260A (es) |
PL (1) | PL2419732T3 (es) |
PT (1) | PT2419732T (es) |
RS (1) | RS59896B1 (es) |
RU (1) | RU2559570C2 (es) |
SG (1) | SG175239A1 (es) |
SI (1) | SI2419732T1 (es) |
WO (1) | WO2010121000A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
ES2685436T3 (es) | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
UA118645C2 (uk) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін |
EP2146707A2 (en) * | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
AU2010236382B2 (en) | 2009-04-15 | 2016-01-14 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
AU2011230512B2 (en) | 2010-03-26 | 2016-09-15 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
WO2012129371A2 (en) * | 2011-03-22 | 2012-09-27 | Nant Holdings Ip, Llc | Reasoning engines |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
EP2790675B1 (en) | 2011-12-14 | 2019-07-03 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
WO2013115559A1 (ko) * | 2012-01-30 | 2013-08-08 | 성균관대학교 산학협력단 | 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법 |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
MX370662B (es) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
BR112020018910A2 (pt) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina |
AU2020375810A1 (en) * | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
US20220347193A1 (en) * | 2021-04-28 | 2022-11-03 | New Jersey Institute Of Technology | Targeted Nanoparticle For The Treatment Of Traumatic Brain Injury And Other CNS Diseases |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1256110B (it) * | 1992-11-23 | 1995-11-28 | Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata | |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US20070117862A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
JP2930421B2 (ja) * | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
GB9519197D0 (en) | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
US5750361A (en) | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
US6537539B2 (en) | 1996-01-11 | 2003-03-25 | Human Genome Sciences, Inc. | Immune cell cytokine |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6221614B1 (en) | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
US6719988B2 (en) * | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Antiseptic compositions for inactivating prions |
CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US6150172A (en) | 1999-01-08 | 2000-11-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method and kit for extracting prion protein |
WO2000064437A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
EP1091877B1 (de) | 1999-04-30 | 2005-05-25 | Krones Ag | Verfahren und vorrichtung zum aufbringen von etikettenhülsen auf gegenstände |
AU784416B2 (en) | 1999-05-21 | 2006-03-30 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
ATE555666T1 (de) | 2002-05-23 | 2012-05-15 | Ortho Clinical Diagnostics Inc | Einfang, konzentration und quantifizierung eines abnormalen prionproteins aus biologischen flüssigkeiten mittels tiefenfiltration |
EP1520733B1 (en) | 2002-07-05 | 2009-10-28 | The Yokohama Rubber Co., Ltd. | Pneumatic tire for ice-bound or snow-covered road |
EP2317317B1 (en) * | 2002-12-03 | 2014-11-26 | North Carolina State University | Prion protein ligands and methods of use |
ES2685436T3 (es) * | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
KR20150108943A (ko) | 2002-12-09 | 2015-09-30 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
SG187269A1 (en) | 2003-04-04 | 2013-02-28 | Univ North Carolina State | Prion protein binding materials and methods of use |
US7510848B2 (en) * | 2003-04-04 | 2009-03-31 | North Carolina State University | Prion protein binding materials and methods of use |
GB0416699D0 (en) * | 2004-07-27 | 2004-09-01 | Prometic Biosciences Ltd | Prion protein ligands and methods of use |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
ES2719093T3 (es) * | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
EP2056812A1 (en) | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
UA118645C2 (uk) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін |
EP2146707A2 (en) | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
CA2746129A1 (en) | 2008-12-11 | 2010-06-17 | Abraxis Bioscience, Llc | Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals |
NZ595189A (en) | 2009-03-13 | 2013-08-30 | Abraxis Bioscience Llc | Combination therapy with thiocolchicine derivatives |
AU2010233097B2 (en) | 2009-04-10 | 2016-04-07 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
AU2010236382B2 (en) * | 2009-04-15 | 2016-01-14 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
PT2470173E (pt) | 2009-08-25 | 2016-06-15 | Abraxis Bioscience Llc | Terapia de combinação com composições nanoparticuladas de taxano e inibidores hedgehog |
AU2011230512B2 (en) | 2010-03-26 | 2016-09-15 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
MX364637B (es) * | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
MX343671B (es) | 2010-06-02 | 2016-11-16 | Abraxis Bioscience Llc * | Metodos de tratamiento de cancer de vejiga. |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
EP3056201A1 (en) | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
EP2790675B1 (en) | 2011-12-14 | 2019-07-03 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
MX370662B (es) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
US20160015817A1 (en) | 2013-03-13 | 2016-01-21 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
CA2990703C (en) | 2015-06-29 | 2024-04-30 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
AU2016287508B2 (en) | 2015-06-29 | 2021-10-14 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2010
- 2010-04-15 AU AU2010236382A patent/AU2010236382B2/en active Active
- 2010-04-15 SG SG2011075264A patent/SG175239A1/en unknown
- 2010-04-15 RS RS20191601A patent/RS59896B1/sr unknown
- 2010-04-15 PL PL10765167T patent/PL2419732T3/pl unknown
- 2010-04-15 EP EP19192486.9A patent/EP3626233A1/en not_active Withdrawn
- 2010-04-15 ME MEP-2019-364A patent/ME03596B/me unknown
- 2010-04-15 RU RU2011146132/15A patent/RU2559570C2/ru active
- 2010-04-15 JP JP2012506210A patent/JP5781500B2/ja active Active
- 2010-04-15 KR KR1020117027031A patent/KR20120044279A/ko not_active Application Discontinuation
- 2010-04-15 HU HUE10765167A patent/HUE047376T2/hu unknown
- 2010-04-15 CN CN201080026604.3A patent/CN102460167B/zh active Active
- 2010-04-15 LT LTEP10765167.1T patent/LT2419732T/lt unknown
- 2010-04-15 BR BRPI1012525-6A patent/BRPI1012525A2/pt not_active Application Discontinuation
- 2010-04-15 US US12/761,292 patent/US20100297243A1/en not_active Abandoned
- 2010-04-15 EP EP10765167.1A patent/EP2419732B1/en active Active
- 2010-04-15 PT PT107651671T patent/PT2419732T/pt unknown
- 2010-04-15 WO PCT/US2010/031197 patent/WO2010121000A1/en active Application Filing
- 2010-04-15 DK DK10765167.1T patent/DK2419732T3/da active
- 2010-04-15 SI SI201031963T patent/SI2419732T1/sl unknown
- 2010-04-15 MY MYPI2011004956A patent/MY175260A/en unknown
- 2010-04-15 MX MX2011010825A patent/MX340055B/es active IP Right Grant
- 2010-04-15 ES ES10765167T patent/ES2764100T3/es active Active
- 2010-04-15 CA CA2758913A patent/CA2758913A1/en not_active Abandoned
-
2011
- 2011-10-23 IL IL215765A patent/IL215765A/en active IP Right Grant
-
2014
- 2014-02-26 US US14/191,279 patent/US9446003B2/en active Active
-
2015
- 2015-04-24 JP JP2015089364A patent/JP6433371B2/ja active Active
-
2016
- 2016-08-17 US US15/239,680 patent/US10206887B2/en active Active
- 2016-11-24 JP JP2016227715A patent/JP2017061537A/ja active Pending
-
2019
- 2019-12-11 CY CY20191101294T patent/CY1122617T1/el unknown
- 2019-12-16 HR HRP20192259TT patent/HRP20192259T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340055B (es) | Metodos y composiciones de nanoparticulas sin priones. | |
PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
CA2865011C (en) | Methods and compositions for treating huntington's disease | |
IN2012DN02737A (es) | ||
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
WO2011047087A3 (en) | Protein detection via nanoreporters | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MX2010006576A (es) | Composiciones y metodos para producir isopreno. | |
MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
AU2012209332A8 (en) | Methods and compositions for preparing noribogaine from voacangine | |
JO3635B1 (ar) | مركبات صيدلانية صلبة وطرق لانتاجها | |
MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
MX357227B (es) | Nanoparticulas basadas en lipidos. | |
MY155330A (en) | Methods for salt production | |
MY161601A (en) | Films and compositions comprising the same | |
AU321832S (en) | Neck support | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
IN2012DN03404A (es) | ||
MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
MX2011013790A (es) | Derivados de flavina. | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
PH12014501367A1 (en) | Processes for making magnolol and derivatives thereof | |
TW200833751A (en) | Method for preparing polyester nanocomposites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |